Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study
单位:[1]Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China[2]Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou, Guangdong, Peoples R China[3]Jiangsu Canc Hosp, Med Oncol, Nanjing, Jiangsu, Peoples R China[4]Shanghai First Peoples Hosp, Med Oncol, Ctr Canc, Shanghai, Peoples R China[5]Zhejiang Univ, Coll Med, Affiliated Hosp 1, Med Oncol, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[6]Fudan Univ, Tumor Hosp, Med Oncol, Shanghai, Peoples R China[7]NanFang Hosp, Ctr Canc, Med Oncol, Guangzhou, Guangdong, Peoples R China[8]Shantou Univ, Coll Med, Affiliated Tumor Hosp, Med Oncol, Shantou, Peoples R China[9]Fujian Med Univ, Union Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China[10]Harbin Med Univ, Affiliated Tumor Hosp, Med Oncol, Haerbin, Peoples R China[11]Wuhan Tongji Hosp, Oncol, Wuhan, Hubei, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[12]Liuzhou Workers Hosp, Med Oncol, Liuzhou, Peoples R China[13]Sichuan Univ, West China Hosp, Ctr Canc, Med Oncol, Chengdu, Sichuan, Peoples R China四川大学华西医院[14]Beijing 301 Hosp, Med Oncol, Beijing, Peoples R China[15]Linyi Tumour Hosp, Med Oncol, Linyi, Peoples R China[16]Beijing Canc Hosp, Beijing, Peoples R China[17]Shanghai Junshi Biosci Co, Med Clin, Shanghai, Peoples R China
第一作者单位:[1]Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
Xu R.,Wang F. H.,Feng F. J.,et al.Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study[J].ANNALS OF ONCOLOGY.2018,29:
APA:
Xu, R.,Wang, F. H.,Feng, F. J.,Li, Q.,Xu, N....&Yao, S..(2018).Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study.ANNALS OF ONCOLOGY,29,
MLA:
Xu, R.,et al."Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study".ANNALS OF ONCOLOGY 29.(2018)